Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2008

Conditions
OsteoarthritisOsteoarthritis, Hip
Interventions
DRUG

Naproxcinod

750 mg, bid

DRUG

Naproxen

500 mg, bid

DRUG

Placebo

bid

Trial Locations (48)

14609

Rochester

16635

Duncansville

19047

Penndel

23606

Newport News

29204

Columbia

29621

Anderson

32117

Daytona Beach

32720

DeLand

33134

Coral Gables

33458

Jupiter

33916

Fort Meyers

35406

Tuscaloosa

36106

Montgomery

36608

Mobile

37660

Kingsport

40291

Louisville

44122

Cleveland

45005

Franklin

45224

Cincinnati

48602

Saginaw

49009

Kalamazoo

73008

Bethany

77627

Nederland

78217

San Antonio

78705

Austin

80234

Northglenn

85016

Phoenix

85213

Mesa

85224

Chandler

92120

San Diego

93111

Santa Barbara

95628

Fair Oaks

01960

Peabody

08009

Berlin

07801

Dover

02886

Warwick

V5G 1T4

Burnaby

V3K 3P4

Coquitlam

V5Z 1K3

Vancouver

N0N 1G0

Corunna

N2M 5N6

Kitchener

L4T 4J2

Mississauga

L3Y 5G8

Newmarket

M9W 4L6

Toronto

G1V 3M7

Québec

G8Z 1Y2

Trois-Rivières

S4P 3X1

Regina

S7K 3H3

Saskatoon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NicOx

INDUSTRY